

***In vitro* Evaluation of Mesh-reinforced Absorbable Self-setting Composite Adhesive Bone Cement**

K. D. Gray, Jr., S. J. Peniston, R. T. Pace, S. W. Shalaby
Poly-Med, Inc., Anderson, SC

Statement of Purpose: Preliminary results demonstrating the feasibility of producing new self-setting adhesive bone cements based on methoxypropyl cyanoacrylate and inorganic phosphates prompted the exploration of fiber-reinforced absorbable self-setting composite bone fillers for treating different forms of bone defects.¹⁻³ This led to conducting an exploratory study on fiber-reinforced absorbable self-setting composite bone filler based on methoxypropyl cyanoacrylate reinforced with warp-knitted mesh made of multifilament yarn of a high-lactide copolymer.⁴⁻⁶ Preliminary results of the exploratory study demonstrated the feasibility of producing a self-setting composite adhesive bone filler with promising properties for repairing bone defects, including those in the maxillofacial and cranial regions.⁶ A logical extension of these activities was to conduct a focused study on the preparation and *in vitro* evaluation of representative forms of these composites as discussed in the present communication.

Methods: Self-setting, absorbable bone cements were prepared from methoxypropyl cyanoacrylate and either (1) calcium phosphate with potassium phosphate (SCC-P type composites) or (2) calcium phosphate in combination with calcium silicate (SCC-PS type composites). All composites were reinforced with warp-knitted mesh made of multifilament yarn of a high-lactide copolymer. Using molds constructed from stainless steel and Teflon, mesh-reinforced samples of 3 in. x 3 in. x 2 mm were prepared for SCC-P type and SCC-PS type bone cements. Samples of approximately 1 cm x 5 cm x 2 mm were cut from original molded samples and evaluated by mechanical three-point bending. *In vitro* mass loss testing was evaluated after samples were incubated in deionized water at 50 °C for 28 days.

Results: Compositions of each sample are described in Table I. As expected, *in vitro* mass loss for mesh-reinforced composites over a 28 day period were similar to those of unreinforced samples of the same composition (Table II). Overall, SCC-PS3 had a greater mass loss than SCC-PS12 at all time periods tested. Results from three-point bending tests revealed that the CaSiO₃-containing SCC-PS3 composites possessed better mechanical properties than the K₂HPO₄-containing SCC-P12 (Table III). However, the mechanical properties of both mesh reinforced samples for SCC-PS3 and SCC-PS12 were similar.

Table I. Compositions of SCC-P and SCC-PS-type Composites Used to Prepare Mesh-reinforced Samples

Sample SCC-	Solid / MPC, g/mL	Composition of Solid Component; weight ratio
PS3	50/50	50 / 50, CaHPO ₄ / CaSiO ₃
P12	60/40	95 / 5, CaHPO ₄ / K ₂ HPO ₄

Table II. *In Vitro* Mass Loss Data at 50 °C

Sample SCC-	Percent Mass Loss			
	7 Days	14 Days	21 Days	28 Days
PS3	34.8%	38.2%	41.0%	43.1%
PS3 Reinforced	35.9%	38.5%	37.7%	40.9%
P12	2.4%	4.2%	6.2%	8.8%
P12 Reinforced	9.4%	4.7%	6.3%	11.1%

Table III. Three-point bending Data for Mesh-reinforced SCC-P12 and SCC-PS3

Sample SCC-	Peak Load (N)	Peak Stress (psi)	Modulus (N/mm ²)	Energy Under Curve (N/cm ³)
PS3	51	356	76	39
PS3 Reinforced	33	245	64	34
P12	29	217	32	131
P12 Reinforced	34	242	41	70

Conclusions: Similar mass loss for mesh-reinforced composites and unreinforced composites of the same composition indicate that the inclusion of a high-lactide copolymer into our self-setting adhesive bone cements does not significantly alter the absorption profile.

However, mesh-reinforcement appears to have improved the mechanical profile of the SCC-P12 composite while diminishing the mechanical profile of the SCC-PS3 composite. These results suggest that mesh reinforcement is more suitable for the SCC-P type composites than the SCC-PS type. Future studies will verify the effect of mesh-reinforcement on the mechanical profile of different composites.

References:

- Shalaby, S.W. et al., U.S. Patent app. 11/601,994 (2006).
- Shalaby, S.W. et al., U.S. Patent app. 12/080,649 (2008).
- Shalaby, S.W. et al., *Trans Soc Biomater*, **31**, 519 (2009).
- Shalaby, S.W. U.S. Patent 7,048,753 (2006).
- Anneaux, B.L. et al., *Trans Soc Biomater*, **25**, 659 (2002).
- Vaughn, M.A. et al., *Trans Soc Biomater*, **31**, 522 (2009).

Acknowledgement: This work is supported in part by a Phase I National Institutes of Health ARRA Grant No. R43 AR056898-01-A1.